Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus SEFFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus SEFFIN.
CEFOBID vs SEFFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
SEFFIN is a brand name for cefazolin, a first-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
Terminal elimination half-life is approximately 0.5-1 hour in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary excretion (<5%) and fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic